Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents
Jean-Eric Tarride,1,2 Natasha Burke,1,2 Camilla Von Keyserlingk,1,2 Daria O'Reilly,1,2 Feng Xie,1,2 Ron Goeree1,2
1Programs for Assessment of Technology in Health (PATH) Research Institute, St Joseph's Healthcare Hamilton, Hamilton, 2Department of Clinical Epidemiology and Biostatistics, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada
Background: Influenza affects all age groups and is common in children. Between 15% and 42% of preschool- and school-aged children experience influenza each season. Recently, intranasal live attenuated influenza vaccine, trivalent (LAIV) has been approved in Canada.
Objective: The objective of this study was to determine the cost-effectiveness of LAIV compared with that of the injectable inactivated influenza vaccine, trivalent (TIV) in Canadian children and adolescents from both a payer (eg. Ministry of Health) perspective and a societal perspective.
Methods: A cost-effectiveness model comparing LAIV and TIV in children aged 24–59 months old was supplemented by primary (ie, a survey of 144 Canadian physicians) and secondary (eg, literature) data to model children aged 2–17 years old. Parameter uncertainty was addressed through univariate and probability analyses.
Results: Although LAIV increased vaccination costs when compared to TIV, LAIV reduced the number of influenza cases and lowered the number of hospitalizations, emergency room visits, outpatient visits, and parents’ days lost from work. The estimated offsets in direct and societal costs saved were CAD$4.20 and CAD$35.34, respectively, per vaccinated child aged 2–17 years old. When costs and outcomes were considered, LAIV when compared to TIV, was the dominant strategy. At a willingness to pay of CAD$50,000 per quality adjusted life year gained, or CAD$100,000 per quality adjusted life year gained, the probabilistic results indicated that the probability of LAIV being cost-effective was almost 1.
Conclusions: LAIV reduces the burden of influenza in children and adolescents. Consistent with previously reported results, vaccinating children with LAIV, rather than TIV, is the dominant strategy from both a societal perspective and a Ministry of Health perspective.
Keywords: influenza, vaccine, children, cost-effectiveness
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Other article by this author:
Health status, hospitalizations, day procedures, and physician costs associated with body mass index (BMI) levels in Ontario, Canada
Tarride JE, Haq M, Taylor VH, Sharma AM, Nakhai-Pour HR, O'Reilly D, Xie F, Dolovich L, Goeree R
Published Date: 24 January 2012
Readers of this article also read:
Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy
Schwander B, Ravera S, Giuliani G, Nuijten M, Walzer S
Published Date: 3 September 2012
Studying the effect of particle size and coating type on the blood kinetics of superparamagnetic iron oxide nanoparticles
Roohi F, Lohrke J, Ide A, Schuetz G, Dassler K
Published Date: 10 August 2012
Drug use and self-medication among children with respiratory illness or diarrhea in a rural district in Vietnam: a qualitative study
Le TH, Ottosson E, Nguyen TKC, Kim BG, Allebeck P
Published Date: 13 September 2011
Describing the hexapeptide identity platform between the influenza A H5N1 and Homo sapiens proteomes
Published Date: 9 September 2010
Andrés Uribe-Sánchez, Alex Savachkin
Published Date: 7 July 2010
Gena Kanas, Libby Morimoto, Fionna Mowat, et al
Published Date: 24 February 2010
Eldo E Frezza, Mitchell Wacthell, Bradley Ewing
Published Date: 10 December 2009
Eduardo Pimenta, Suzanne Oparil
Published Date: 19 May 2009
Gene silencing in the therapy of influenza and other respiratory diseases: Targeting to RNase P by use of External Guide Sequences (EGS)
David H Dreyfus, S Mark Tompkins, Ramsay Fuleihan, Lucy Y Ghoda
Published Date: 22 January 2007
Giorgio L Colombo, Antonio Ferro, Marta Vinci, Maria Zordan, Giulio Serra
Published Date: 20 January 2006